吉非替尼联合多西他赛用于治疗晚期EGFR突变阳性非小细胞肺癌的疗效观察  

Efficacy of Gefitinib Combined with Docetaxel in the Treatment of Advanced EGFR Mutation-positive Non-small Cell Lung Cancer

作　　者：胡晟 张群 李伟 HU Sheng;ZHANG Qun;LI Wei(First People's Hospital of Yancheng,Yancheng,224001)

机构地区：[1]江苏省盐城市第一人民医院

出　　处：《实用癌症杂志》2019年第9期1557-1559,共3页The Practical Journal of Cancer

摘　　要：目的探讨吉非替尼联合多西他赛治疗晚期EGFR突变阳性非小细胞肺癌的疗效。方法将70例晚期非小细胞肺癌患者随机分为2组,每组35例。对照组采用多西他赛和顺铂治疗,治疗组采用多西他赛和吉非替尼治疗。对比2组用药后的临床疗效、生活质量评分、疾病进展时间和平均生存时间以及不良反应发生率。结果治疗组客观缓解率和临床获益率显著高于对照组(P<0.05)。2组患者治疗后认知、躯体、社会功能、情绪和角色评分显著高于治疗前(P<0.05);并且治疗组患者认知、躯体、社会功能、情绪和角色评分显著高于对照组(P<0.05)。治疗组患者疾病进展时间和平均生存时间显著长于对照组(P<0.05)。2组胃肠道反应、中性粒细胞减少、血小板减少和肝功能异常等不良反应发生率差异无统计学意义(P>0.05)。结论吉非替尼联合多西他赛用于治疗EGFR突变阳性晚期非小细胞肺癌具有较好的治疗效果,患者耐受性好,安全性较好,并且能改善患者生活质量,值得在临床上推广应用。Objective To investigate the efficacy of gefitinib combined with docetaxel in the treatment of advanced EGFR mutation-positive non-small cell lung cancer.Methods 70 patients with advanced NSCLC were randomly divided into 2 groups,35 patients in each group.The control group was treated with docetaxel and cisplatin,and the treatment group with docetaxel and gefitinib.The clinical efficacy,quality of life score,time of disease progression,mean survival time and incidence of adverse reactions were compared between the 2 groups.Results The objective remission rate and clinical benefit rate in the treatment group were significantly higher than those of the control group(P<0.05).The scores of cognition,body,social function,emotion and role of patients in the 2 groups after treatment were significantly higher than those before treatment(P<0.05).In addition,the cognitive,physical,social,emotional and role scores of patients in the treatment group were significantly higher than those of the control group(P<0.05).The time of disease progression and average survival time in the treatment group were significantly better than those of the control group(P<0.05).There was no significant difference in the incidence of adverse reactions such as gastrointestinal reaction,neutropenia,thrombocytopenia and liver dysfunction between the two groups(P>0.05).Conclusion gefitinib combined with docetaxel in the treatment of advanced non-small cell lung cancer with positive EGFR mutation has a good therapeutic effect,good patient tolerance,good safety,and can improve the quality of life of patients,which is worthy of clinical application.

关 键 词：吉非替尼 多西他赛 晚期EGFR突变阳性非小细胞肺癌 生存质量 

分 类 号：R734.2[医药卫生—肿瘤]